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Abstract
A genome wide association study (GWAS) typically results in a few highly significant ‘hits’ and a much larger set of
suggestive signals (‘near-hits’). The latter group are expected to be a mixture of true and false associations. One promising
strategy to help separate these is to use functional annotations for prioritisation of variants for follow-up. A key task is to
determine which annotations might prove most valuable. We address this question by examining the functional
annotations of previously published GWAS hits. We explore three annotation categories: non-synonymous SNPs (nsSNPs),
promoter SNPs and cis expression quantitative trait loci (eQTLs) in open chromatin regions. We demonstrate that GWAS hit
SNPs are enriched for these three functional categories, and that it would be appropriate to provide a higher weighting for
such SNPs when performing Bayesian association analyses. For GWAS studies, our analyses suggest the use of a Bayes
Factor of about 4 for cis eQTL SNPs within regions of open chromatin, 3 for nsSNPs and 2 for promoter SNPs.
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Introduction
New clues about the aetiology of complex genetic diseases have
been provided by genome-wide association studies (GWAS) [1].
Since SNPs across the genome are investigated in GWAS, this
allows such studies to identify causal variants which may never
have been previously suspected to be involved in the trait.
Notwithstanding the advantages of this ‘hypothesis-free’ or
‘hypothesis -neutral’ approach, it has become clear that effect
sizes of many of the common variants involved in complex diseases
are so small that even very large GWAS do not have full power to
detect them [2]. This leads to a situation where, while each GWAS
may result in a small number of genome-wide significant hits
(those for which p-values are low enough to distinguish from false
associations that occur by chance), there are a large number of
true hits hidden within the association signals with p-values that
are suggestive but not conclusive of true association.
Several lines of evidence suggest that these near hits do indeed
contain some real association signals. Firstly, quantile-quantile
plots of GWAS association p-values often show a departure from
null expectation that extends into the ranked SNPs below the
genomewide significance threshold [3]. Secondly, various forms of
pathway analysis have reported significant biological dependency
between near hit SNPs [4]. Thirdly, and most directly, GWAS
meta-analysis often finds new hits that only appeared as near hits
in smaller GWASs [5,6].
Prioritization of near hits for follow-up may be more effective if
functional information is combined with the GWAS p-values.
There is already evidence that causative SNPs for a wide range of
traits are enriched for certain functional categories [7] [8] and an
increasing amount of annotation is available that could be used for
such studies. There are annotations relating to gene structure,
predicted function of nsSNPs, regulatory regions, DNA structure
and many more [9]. Various statistical methods are now available
for the analysis of p-values that have been weighted according to
some user-defined scheme [10,11,12,13,14]. However, a key
aspect of all these studies is that they use subjective weighting
schemes. In this study, we propose empirically derived weightings
within a Bayesian framework.
One way to arrive at an objective, empirically based weighing
scheme is to use the observed preponderance of functional
annotations in established GWAS hits as a guide to weighting of
‘near hit’ GWAS SNPs. GWAS data are more appropriate for this
purpose than candidate gene genotyping data, as the SNPs typed
in the latter type of study are often selected on the basis of
annotation and therefore could produce biased results. Two
recently published databases of GWAS hits ([15] [16], hereafter
referred to as ‘Hindorff’ and ‘Johnson’) have provided the
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contain .2000 SNPs with a low p-value for association in at least
one GWAS, although there are several differences between the
datasets which are discussed below. Both groups performed some
analysis of the data. Hindorff et al analysed hits with a p-value
,5610
28 whereas Johnson and O’Donnell analysed all the results
in their dataset (p-values ,0.05) [7,16]. Hindorff et al looked at 20
different annotations and established that non-synonymous sites
and 5kb promoter regions are enriched in GWAS hits relative to
regular GWAS panel SNPs. Johnson and O’Donnell demonstrat-
ed that SNPs that are hits in multiple studies are more likely to be
true hits. They also described an over representation of hits in
genes related to cell adhesion functions. More recently Nicolae
et al [17] have established an overrepresentation of expression
QTLs (eQTLs) in the Hindorff database.
It is not clear how dataset-specific these previous findings might
be. In this paper, we compare and contrast two GWAS hit datasets
and perform sensitivity analysis to gauge the robustness of
annotation enrichment under different conditions. We focus on
three annotations from three different categories, non-synonymous
SNPs (nsSNPs), promoter SNPs and cis expression QTLs (eQTLs)
lying in open chromatin regions, representing three major classes
of annotation information: protein changes, gene regulation and
gene expression. We determine if these annotations are enriched
across both datasets carrying out some additional analysis to verify
the robustness of the findings. We find that Hindorff’s results in
relation to nsSNPs and promoter SNPs and Nicolae’s results
relating to eQTLs are broadly repeated across both datasets. We
show how these findings can be built into a Bayesian analysis of
association results.
Methods
GWAS hit SNPs
We used two published GWAS datasets: ‘Hindorff’ ([15]) and
‘Johnson’ ([16]). Both datasets were compiled using literature
searches of Pubmed and other sources. The Hindorff dataset has a
p-value cut-off of 10
25 (although Hindorff et al [7] only performed
analyses on SNPs with a p-value less than 10
28), while the Johnson
dataset uses a p-value cut-off of 0.05. The Hindorff dataset is
continually updated whereas the Johnson one is not. The latter
includes all GWAS published up until 1
st March 2008. We
downloaded the Hindorff dataset on the 21
st May 2010, at which
point it contained 2727 unique SNPs with results for single marker
analyses. The Johnson dataset contained 52546 SNPs, but we
performed most of our analyses on data with p-values less than
10
25 (4086 SNPs). After noting a large excess of SNPs in the major
histo-compatibility (MHC) region in the Johnson dataset we
filtered out SNPs from this region (chr6:25809985-33486934) in
both datasets, as results from this region could be unrepresentative
of results throughout the rest of the genome due to the high density
of genes and extensive long range linkage disequilibrium. This left
2115 unique SNPs from 425 studies in the Hindorff dataset and
2695 from 96 studies in the Johnson dataset (constrained to
p,10
25). We also filtered out hit SNPs that were not on the
original GWAS panels as they are often selected on the basis of
annotation to support the replication. Except where otherwise
stated all results presented relate to this subset of the data.
GWAS panel SNPs
We adopted a sensitivity analysis approach in which we
contrasted results obtained under two very different scenarios,
representing two extreme possible endpoints of average GWAS
panel SNP composition. In one we assumed all GWASs had used
the Affymetrix Mapping 500K panel (hereafter ‘Affy500’) and in
the other that all GWASs had used the Illumina HumanHap
550K panel (hereafter ‘Illu550’). Both panels have been widely
used in GWASs to date, but reflect different strategies for marker
selection. Illumina selected tagging SNPs whereas Affymetrix
selected SNPs based on assay availability and minor allele
frequency. The proportion of SNPs with a MAF less than 0.1
on the Illu550 is 22% whereas the proportion on the Affy500 is
34%. In addition to these two extreme approaches, we considered
a compromise GWAS panel set comprising the union of these two
panels (hereafter ‘Affy500+Illu550’).
Annotation
We chose three annotation categories; non-synonymous SNPs
(nsSNPs), expression quantitative trait loci (eQTLs) and promoter
region SNPs. Non-synonymous SNPs alter the amino acid
sequence of a gene product, we downloaded these from the
UCSC browser selecting nonsense (premature termination codons)
and missense mutations from the dbSNP version 130 table.
eQTLs are excellent candidates for GWAS hits as they are
thought to be causally involved in complex traits and may be more
closely correlated to the genotype than the complex trait itself. We
defined and selected eQTLs from a study of global gene expression
in lymphoblast cell lines (LCLs) [18]. Some 55,000 transcripts
representing 21,000 genes were investigated and approximately
15,000 transcripts (from 7,000 genes) demonstrated heritability.
These transcripts were tested as a GWAS and all SNP-transcript
pairs with regression p-values ,0.001 were retained. We defined
eQTLs based on the rank of this p-value. In one set of analyses we
used a stringent cut-off, defining eQTLs as only those that had a p-
value in the top 20,000. For the other set of analysis we used p-
values in the top 100,000. We performed analysis on all eQTLs
and also on cis-eQTLs (those within 200 kb of the transcript they
are associated with). These selection criteria allowed us to explore
a number of approaches to defining eQTLs. We also identified
eQTLs within open chromatin regions as these are much more
likely to be involved in regulation of expression. We used evidence
of open chromatin in multiple cell lines from the Duke/UNC/
UT-Austin/EBI ENCODE group made available on UCSC.
Open chromatin regions were identified using two independent
and complementary methods: DNaseI hypersensitivity (HS)
and Formaldehyde-Assisted Isolation of Regulatory Elements
(FAIRE), combined with chromatin immunoprecipitation (ChIP)
for selected regulatory proteins. Each method was verified by two
detection platforms: Illumina (formerly Solexa) sequencing by
synthesis, and high-resolution 1% ENCODE tiled microarrays
supplied by NimbleGen.
We used the First exon finder (firstEF) program to identify
putative promoter regions, defined as the 570 bp immediately
upstream of the first exon [19]. Many genes have completely non-
coding first exons (i.e. fall entirely within the 5’ UTR). It is
therefore important to check that the reported first exon for a gene
does not have an upstream splice donor as this would suggest that
the true first exon (and promoter region) has not been correctly
identified. FirstEF identifies splice donor sites and uses discrim-
inant functions to identify true first exons and their promoters
regions. We ran FirstEF on the hg18 (build 36) table within the
UCSC genome browser, it identified 74737 promoters (many
more than the number of putative genes because many genes have
alternative promoters and alternative first exons).
Our approach to testing for annotation enrichment was to
compare the proportion of annotated SNPs in the GWAS hit SNP
sets with the GWAS panel SNP sets. We determined standard
error bars and statistical significance based on expected binomial
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annotation classes in the GWAS panel sets was large enough to
result in negligible error by comparison).
Linkage disequilibrium (LD) proxies
GWAS panels do not include every SNP in the genome, and it is
expected that many GWAS hits will only be markers for true
causal variants, lying outside the GWAS panel, that are associated
via linkage disequilibrium or ‘tagging’. We address this issue by
annotating our GWAS SNPs (both ‘hits’ and ‘nulls’) via LD-proxy.
A SNP was defined to be LD-proxy-annotated if it was in linkage
disequilibrium with an annotated SNP with r
2.=0.8. We used
the SNAP web-tool [20] to determine the LD proxies for all
GWAS SNPs, based on the HapMap Phase 2 CEU reference
population [21]. This population was chosen because most GWAS
studies in both datasets are largely made up of Caucasian
individuals.
We note that eQTL annotations already have an element of
linkage disequilibrium ‘built in’, as any SNP labelled an eQTL
may itself be only tagging a nearby causal SNP. However, our
eQTL dataset derives from a smaller GWAS panel (Illumina
300k), making further extension via LD-proxy necessary.
Bayes Factors for Bayesian analysis
Bayesian analysis provides the most suitable framework for
combining annotation information with evidence from an
association study [22]. The posterior odds (Opost) of true
association (meaning a direct or indirect causal effect) for the trait
of interest at a given SNP are defined as the ratio of the
conditional probability of causality, given the annotation and
association data, to the conditional probability of non-causality:
Opost~
Pr(CausalDAnnotData,AssocData)
Pr(NotCausalDAnnotData,AssocData)
This quantity can be found as the product of the following ratios
(given that the annotation data and association data are
independent once conditioned on causality):
Opost~OpriorxBFannotxBFassoc
Where Oprior are the prior odds before seeing any data, thus
Oprior = Pr(Causal)/Pr(Not Causal); BFannot is the Bayes Factor
for the annotation data, thus BFannot = Pr(Annot Data | Causal)/
Pr (Annot Data | Not Causal); and BFassoc is the Bayes Factor for
the association data, thus BFassoc = Pr(Assoc Data | Causal)/Pr
(Assoc Data | Not Causal).
Note that our definition of ‘true association’ includes the
possibility of indirect association via linkage disequilibrium. To
account for this, we import annotation data from other SNPs in
LD, as we describe above. We also note that BFassoc will typically
refer to a hypothesis of causality for a specific phenotype, whereas
the BFannot values that we consider below refer to a hypothesis of
causality for any phenotype that has been tested in a GWAS. Our
method is therefore motivated by the idea that the BFannot values
obtained under a general-phenotype definition of causality are a
reasonable guide to the BFannot values one would obtain for the
specific phenotype in question.
The prior odds, Oprior, are set in advance, and are usually set to
reflect a low prior belief that any one given SNP in the human
genome is causally related to the phenotype in question (as indeed
reflected by the small number of GWAS hits found so far for most
complex traits). For example, Oprior =10
25 was used by the
Welcome Trust Case Control Consortium [2]. In cases where only
the relative ranking of SNPs is of interest (for example, where a
fixed number of SNPs to be taken forward for follow-up), then the
value of Oprior is unimportant as it will not affect the relative
rankings of Opost.
The Bayes Factor for association, BFassoc, is calculable from
GWAS data either via direct computation of the relevant integral
[2] or via an approximation which removes the need for
integration [23].
The Bayes Factor for annotation, BFannot is estimated
empirically from the GWAS hit data. The estimated value is the
proportion of a given annotation class seen in the set of hit SNPs
divided by the proportion seen in the set of non-hit SNPs. Since hit
SNPs make up a small fraction of all SNPs, we shall use the
annotation proportion seen in unselected GWAS panel sets for this
latter quantity.
Application to real data
Application of our method to real data would require the
following steps: (1) decide on prior odds (if absolute rather than
relative Opost values are required); (2) calculate BFassoc from
GWAS data; (3) calculate BFannot from GWAS hit database data;
(4) calculate posterior odds using the formula given above. To
facilitate our method, we have made available software for
calculating BFassoc from PLINK output files, and have created a
file containing BFannot values for all the SNPs on the Affy500 and
the Illu550 panels, indicating their annotation status for the three
categories under study as well as BFannot in the range that we
recommend using. These resources are available from our website:
http://www.kcl.ac.uk/schools/medicine/research/genetics/research/
clusters/bse/weale/software.
We tested our method on a real dataset. We compared the rank
of the BFassoc with the rank of the product of the BFassoc and the
BFannot in the WTCCC1 Crohn’s data[2]. We determined the
changes in rank of the 48 loci that have been recently determined
to be involved in the trait only 9 of which were demonstrated to be
strongly associated with the trait in the WTCCC1 study [24].
(Only 48 of the recently published 71 were used because the others
were neither present nor represented by proxies on the Affy500 or
Illu550 panels.) We also determined the rank change for 100 sets
of 48 randomly selected SNPs. We used the Wakefield method to
derive the BFassoc [23].
Results
General annotation enrichment and sensitivity analyses
A higher proportion of SNPs have functional annotation in the
GWAS hit datasets compared to the GWAS panel SNPs (Figure 1
and Table 1). The p-values for all these differences were less than
2.8610
25 which is equivalent to a level of 0.001 after Bonferroni
adjustment for multiple testing.
We observed that the Hindorff dataset had 13.6% of SNPs with
MAF,0.1, while the Johnson dataset had 29.8% of SNPs with
MAF,0.1, a similar figure was seen in the Affy500+Illu550 panel
(27.9%). This bias may be due to the fact that the Hindorff dataset
often only contains the most significant SNP in a region. It is likely
that such SNPs will have a relatively high MAF compared to
others in the region as it is hard for SNPs with very low MAF to
attain small p-values. To test the results for robustness against the
differences in MAF distributions, the proportion of annotation was
compared for SNPs with MAF ,0.1 and SNPs with MAF =.0.1
(Figure 2, panel A). The proportion of annotation was again found
to be lower in the Affy500+Illu550 panel than in either GWAS hit
datasets for all annotations. As the pattern with respect to the
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range, we performed further analyses on the complete datasets
irrespective of MAF.
To establish whether the results from the three categories were
independent, we removed all SNPs that had a multiple annotation
or were a proxy for any SNP in another annotation category. The
patterns remained consistent (Figure 2, panel B). The remaining
analyses were performed on all SNPs, including those with
multiple annotations.
To investigate whether the results were specific to the chosen
‘null’ GWAS panel set, we compared the annotation proportions
seen in the Affy500-only and Illu550-only GWAS panels. Since
different SNP selection strategies were adopted by Affymetrix and
Illumina in constructing their panels, and in particular in the SNP
tagging approach used by Illumina, splitting the GWAS panel
dataset in this way allowed us to perform a sensitivity analysis with
respect to the different SNP selection strategies and their effect on
GWAS panel composition. We found consistently lower propor-
tions of annotation in all three GWAS panel sets, compared to
either GWAS hit sets (Figure 2, panel C). We therefore performed
further analyses using the combined Affy500+Illu550 set.
Estimating Bayes Factors
We suggest the use of Bayes Factors of 0.93 for SNPs without
annotation and within the range of 3.1–4.7 for cis eQTLs in open
chromatin, 2.9–3.5 for nsSNPs, 1.8–2.5 for promoter SNPs. These
ranges take into account the results from both datasets when
proxies of the annotated SNPs with r
2so f.=0.8 are included.
Figure 3 shows that when more stringent p-value thresholds are
used to define GWAS hits, the Bayes Factors increase. This
provides further evidence that annotation enrichment is not due to
some artefact, as this pattern is consistent with the proportion of
true GWAS hits increasing as p-value stringency increases. We
consider Bayes Factors calculated at the p-value cut-off of 10
26 to
be the most appropriate for use. This p-value cut-off balances the
requirement for stringency that will enrich for selection of true hits
and lenience to ensure enough SNPs are included to allow a
reasonably accurate measure of the Bayes Factor.
Linkage disequilibrium proxies
We use ‘LD-proxy-annotations’ (see Methods) to address the
issue that many GWAS hits will not be directly causal, but will
only tag an off-panel causal variant by linkage disequilibrium.
However, our method relies on an arbitrary threshold (r
2.=0.8).
We therefore performed sensitivity analyses on the effect of LD
proxy threshold.
We performed most analysis using proxies with an r
2 of .=0.8
and tested the effect of this cut-off by performing analysis using
proxies with an r
2 of 1, and analyses with no proxies at all. The
variation in threshold did not have much of an impact on the
results (Figure 4). There is some variation in Bayes Factors, but
there is no evidence that those calculated using LD proxies are
systematically biased.
eQTL definition
In our preliminary analysis we investigated cis eQTLs in open
chromatin only selecting the SNPs that had a p-value ranked in
the most significant 100,000. However we also calculated Bayes
Factors for both cis and trans eQTLs and for eQTLs with a p-value
ranked in the most significant 20,000. For each category we also
calculated Bayes Factors for all SNPs as well as only for those
SNPs in open chromatin (Figure 5).
In each direct comparison the SNPs in open chromatin had the
greaterBayesFactor.ThemosthighlysignificantciseQTLcategory
had the greatest Bayes Factor. The increase in stringency and
selection of only cis eQTLs both increase the Bayes Factor but it is
important to note that these are not independent selection criteria.
When the top 20,000 eQTLs are selected 74.9% of these are cis,
when the top 100,000 are selected only 30.3% of these are cis.
Application to real data
The rank of the BFassoc *B F annot was on average 10322 higher
than the rank of the BFassoc for the Crohn’s hits and 205 lower for
the null hits. Furthermore 21 of the Crohn’s hits moved up in rank
while the average number that moved up in the null set was only 4.
Discussion
Our study confirms the hypothesis that there are differences in
the proportion of functional annotation between GWAS hits and
Figure 1. Annotation proportions in the Hindorff and Johnson
GWAS hit datasets and a GWAS panel set. The proportion of
annotation is shown for three different categories (cis eQTL in open
chromatin, nsSNPs and promoter SNPs). ‘‘***’’ indicates p-values
,2.8610
25 (=0.001/36); ‘‘**’’ indicates p-values ,2.8610
24 (=0.01/
36); ‘‘*’’ indicates p-values ,1.4610
23 (=0.05/36). These thresholds
were chosen to reflect a Bonferroni correction of the 36 comparison
tests implicit in Figures 1 and 2. The error bars represent the standard
error of the estimated proportions (normal approximation to binomial
distribution). The GWAS panel set is comprised of a union of Affymetrix
500k and Illumina 550k panels.
doi:10.1371/journal.pone.0014808.g001
Table 1. GWAS SNP set annotation counts (with percentage
of total in brackets).
Hindorff Johnson Affy500+Illu550
Total (hit SNPs: P,10
26) 1219 1576 961605
cis eQTLs in Open Chromatin 46 (3.8) 39 (2.5) 7791 (0.8)
ns SNPs 166 (13.6) 181 (11.5) 37856 (3.9)
promoter SNPs 97 (8) 89 (5.6) 30516 (3.2)
No annotation 1853 (87.6) 2380 (88.3) 908537(94.5)
For the GWAS hit SNP datasets, the number of SNPs with p-values ,10
26 that
fall into each annotation categories is presented. SNPs in each annotation
categories include annotated SNPs and their linkage disequlibrium proxies.
doi:10.1371/journal.pone.0014808.t001
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differences in GWAS panel SNP sets, different GWAS hit lists and
SNP allele frequency. The patterns are also independently seen in
each annotation category. This provides us with reassurance, given
the problems experienced both with accurately capturing all
GWAS hits and with defining a fully appropriate comparative
GWAS panel set. Our study highlights three categories of
functional annotation that appear to provide reliable enrichment
in GWAS data that can be used to empirically estimate Bayes
Factors for Bayesian analysis. Furthermore when applied to real
data our technique increases the rank of SNPs that have later been
shown to be hits.
In order to produce hit SNPs sets with reasonably large
numbers of SNPs, our definition of a GWAS ‘hit’ includes SNPs
with p-values greater than what is typically considered to be
genomewide significant. We accept that this increases the
proportion of false positives in our hit sets. However, our
sensitivity analyses show that annotation enrichment is still
noticeable in hit SNP sets with a lower p-value threshold
definition. We also note that the overall effect of false positives
Figure 2. Annotation proportions of subsets the hit datasets and a selection of GWAS panel sets. The proportion of annotation is shown
for three different categories (cis eQTL in open chromatin, nsSNPs and promoter SNPs). Significance levels and error bars are defined as in Figure 1.
Panel A is stratified by minor allele frequency, panel B contains only SNPs with unique annotations and panel C compares different GWAS panels.
doi:10.1371/journal.pone.0014808.g002
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so it will have a conservative effect on the use of annotation
information in combination with association data.
The robustness of these results across the datasets and indeed
the different ways of defining annotations and GWAS hits is
striking, particularly in relation to the eQTLs. The eQTLs in our
study and Nicolae et al’s [17] were both defined from lymphoblast
cell lines, but the eQTL dataset we used was defined in families
ascertained on the basis of a proband with asthma [18] whereas
Nicolae et al defined eQTLs using HapMap individuals. Nicolae
et al used a p-value cut-off which led them to define 40% of the
Hindorff dataset as eQTLs whereas we used a ranking system that
identified 2.5% of the Hindorff dataset as eQTLs. Furthermore
Nicolae et al controlled for MAF by sampling null SNPs with
matching MAF rather than comparing annotation within different
bins. Despite these differences in data and study design eQTL
enrichment is evident across both studies.
While the patterns of enrichment are broadly consistent, our
study also reveals some differences. The annotation proportions,
and derived Bayes Factors, from the Hindorff dataset are almost
always higher than from the Johnson dataset. There is also a
difference in the ranking of the three categories, in the Hindorff
dataset cis eQTLs always have the highest Bayes Factor and
promoter SNPs the lowest. This is the case in most but not all of
the analysis on the Johnson dataset. This reflects ascertainment
differences between the two datasets. One notable difference is the
number of SNPs included per study, with Johnson including 28 on
average and Hindorff only 5. This can be linked to a number of
factors. When Hindorff et al began collating their dataset they only
included one SNP in each associated region whereas the Johnson
dataset include all of them. The Johnson dataset also included
more hits where the information came from supplementary tables
and/or was derived from an alternate statistical test. The Bayes
Factors are also affected to some extent by the choice of reference
GWAS panel, by the inclusion or exclusion of LD proxies, and by
the choice of p-value threshold used to define GWAS hits.
It is not straightforward to arrive at an appropriate ‘null’ set of
GWAS SNPs, against which the annotation properties of a hit set
can be compared. For example, consider combining the results of
Figure 3. Bayes Factors estimated from GWAS hit sets defined
using a range of p-value cut-offs. The Bayes Factors are shown for
three different categories (cis eQTL in open chromatin, nsSNPs and
promoter SNPs). Panel A shows results derived using the Hindorff
dataset and Panel B results from the Johnson dataset. The GWAS panel
set is comprised of a union of Affymetrix 500k and Illumina 550k panels.
doi:10.1371/journal.pone.0014808.g003
Figure 4. Bayes Factors estimated with and without linkage
disequilibrium proxies for annotated SNPs. The Bayes Factors are
shown for three different categories (cis eQTL in open chromatin,
nsSNPs and promoter SNPs). Panel A shows results derived using the
Hindorff dataset and Panel B results from the Johnson dataset. The
GWAS panel set is comprised of a union of Affymetrix 500k and Illumina
550k panels.
doi:10.1371/journal.pone.0014808.g004
Figure 5. Estimated Bayes Factors for alternative eQTL
definitions. The GWAS panel set is comprised of a union of Affymetrix
500k and Illumina 550k panels.
doi:10.1371/journal.pone.0014808.g005
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500K panel with another that used the Illumina HumanHap
550K panel. These panels share about 15% of SNPs. Should the
annotation information for these SNPs held in common be
counted twice (summation approach) or only once (union
approach)? Our null hypothesis is not that all these GWAS hits
are false (we assume in fact that most are true), but rather that
their location is independent of any annotation information that
may be attached to them. The summation approach is appropriate
if we assume that the GWAS hits in the second study are
independent of the first study (e.g. unconnected diseases, no
common causal genetic mechanisms), while the union approach is
appropriate if the same hits are to be expected (e.g. same or very
similar disease, with both studies well powered). Given that both
datasets contain several GWASs on the same or similar
phenotypes, and given the growing evidence for some causal
effects spanning many diseases, the best situation would lie
somewhere between the two approaches. In addition to this
theoretical uncertainly, there is also considerable practical
uncertainty in ascertaining exactly which panels were used in
each study, especially in studies where more than one panel was
used. Even if the panels are known, the set of SNPs remaining after
QC may not be. The panel composition of each GWAS study is
important because there are between-panel differences in the
selection strategies for panel membership, based on features such
as minor allele frequency, linkage disequilibrium and location (e.g.
genic vs inter-genic), and all of these may impact on the
annotation proportions. Again the consistency of results accross
panels demonstrates the validity of the approach despite these
problems.
We accept that it will be difficult to determine exact values for
empirically derived Bayes Factors. However, there is sufficient
consistency in our study for us to suggest the use of Bayes Factors
within the range of 3.1–4.7 for cis eQTLs in open chromatin, 2.9–
3.5 for nsSNPs and 1.8–2.5 for promoter SNPs. If an investigator
chooses to increase weightings on the annotations they would use
the weight at the top of the range, if they wanted to limit the
influence of the annotation they would use a weight from the
bottom of the range. In those cases where more than one
annotation is attached to a SNP, either directly or via LD proxy,
our datasets are not large enough to present direct empirical
answers. We propose conservatively that the annotation with the
largest Bayes Factor be used in such cases, on the assumption that
a second observed annotation may increase but never decrease the
Bayes Factor of the first annotation.
We allowed GWAS panel and GWAS hit SNPs to acquire
‘‘annotation-via-LD-proxy’’, primarily because GWAS panel are
designed to detect association signals via tagging. In addition to
this the use of proxies increases the size of the datasets that we are
working with. An alternate approach would have been to amplify
the set of SNPs to include all LD proxies of all GWAS panel SNPs,
and indentify ‘‘hits-by-proxy’’ and ‘‘nulls-by-proxy’’. However,
under this approach is is not clear what to do with SNPs which are
simultaneously ‘‘hits-by-proxy’’ and ‘‘nulls-by-proxy’’, a problem
which is avoided by our approach.
In this study we have not differentiated GWAS hits by
phenotype, both because we are interested in general determinants
of causality and because stratifying the GWAS hits in this way
decreases the power to identify differences in the distributions of
the annotation between the datasets. However, we note that using
their alternative approach of defining eQTLs, Nicolae et al [17]
found that the enrichment was present across a number of
different phenotype classes, even those in which you would not
expect expression in the lymphoblast cell lines to play a role in the
disorder.
Due to advances in next generation sequencing technology [25],
large amounts of sequence variant data are now becoming
available, particularly focused on the discovery of rare pathogenic
variants. Bayes Factors can also be used to prioritise hits from such
datasets for follow up. In time, Bayes Factors will need to be
derived on the basis of the results of sequencing experiments as
these become public. In the interim, we note that MAF does not
appear to have a large influence on our estimated Bayes Factors
from GWAS data (Figure 2), which presents the possibility of using
the same Bayes Factors estimated here from GWAS data in
sequence analysis, until such time as enough relevant sequence
data becomes available.
The enrichment signal found in this study for different
functional annotation categories in GWAS hits is sufficiently
consistent, and the size of the enrichment sufficiently large, to
justify its use in Bayesian association analyses. More work is
needed to define the size of the signals in other annotation
categories, and to refine how rare variants identified by next
generation sequencing differ from common variants identified in
GWAS data.
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